Evidence map›Paper›PMID 40162598›Full record

ArticleAllergy2025

Meta-Analysis of PQ Grass 27600 SU Efficacy and Quality of Life From Phase III Trials.

Stefan Zielen, Jonathan A Bernstein, Oliver Pfaar, Lawrence DuBuske, Ralph Mösges, Sven Becker, Fiona Sellwood, Matthias F Kramer, Murray Skinner, Pieter-Jan de Kam

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stefan ZielenDepartment of Pediatrics, University Hospital, Goethe University, Frankfurt, Germany.ORCID https://orcid.org/0000-0003-1204-0627
Jonathan A BernsteinDepartment of Internal Medicine, Division of Rheumatology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.ORCID https://orcid.org/0000-0002-3476-1196
Oliver PfaarSection of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany.ORCID https://orcid.org/0000-0003-4374-9639
Lawrence DuBuskeGeorge Washington University Hospital, Washington, DC, USA.ORCID https://orcid.org/0000-0001-5013-8022
Ralph MösgesIMSB, Medical Faculty University at Cologne, Cologne, Germany.ORCID https://orcid.org/0000-0002-1928-810X
Sven BeckerDepartment for Otorhinolaryngology, Head and Neck Surgery, University of Tuebingen, Tübingen, Germany.ORCID https://orcid.org/0000-0003-1972-3797
Fiona SellwoodAllergy Therapeutics (UK) Plc, Worthing, UK.
Matthias F KramerAllergy Therapeutics (UK) Plc, Worthing, UK.ORCID https://orcid.org/0000-0002-3740-4733
Murray SkinnerAllergy Therapeutics (UK) Plc, Worthing, UK.ORCID https://orcid.org/0009-0008-4935-4316
Pieter-Jan de KamAllergy Therapeutics (UK) Plc, Worthing, UK.ORCID https://orcid.org/0000-0003-0859-4862

Funding

Allergy Therapeutics
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

allergic rhinoconjunctivitisgrass pollen allergymeta‐analysisshort‐course treatmentsubcutaneous immunotherapysublingual immunotherapy

Identifiers

PMID40162598
PMCPMC12261871

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.